Predicting Alzheimer disease from a blood-based biomarker profile
Authors
Samantha C. Burnham, CSIRO Health and Biosecurity
Christopher C. Rowe, University of Melbourne
David Baker, Janssen, Titusville, United States
Ashley I. Bush, University of Melbourne
James D. Doecke, CSIRO Health and Biosecurity
Noel G. Faux, University Michigan
Simon M. LawsFollow
Ralph N. Martins, Edith Cowan UniversityFollow
Paul T. Maruff, Cogstate Ltd
Stuart Lance Macaulay, Commonwealth Scientific and Industrial Research Organization
Stephanie R. Rainey-Smith, Hollywood Private Hospital
Greg R. Savage, Macquarie University
David J. Ames, University of Melbourne
C L. Masters, Macquarie University
William J. Wilson, Commonwealth Scientific and Industrial Research Organization
Victor L. Villemagne, Commonwealth Scientific and Industrial Research Organization
Document Type
Journal Article
Publication Title
Neurology
Publisher
Lippincott Williams and Wilkins / Wolters Kluwer
Place of Publication
United States
School
School of Medical and Health Sciences
RAS ID
21995
Abstract
Objective: We assessed a blood-based signature, which previously demonstrated high accuracy at stratifying individuals with high or low neocortical β-amyloid burden (NAB), to determine whether it could also identify individuals at risk of progression to Alzheimer disease (AD) within 54 months. Methods: We generated the blood-based signature for 585 healthy controls (HCs) and 74 participants with mild cognitive impairment (MCI) from the Australian Imaging, Biomarkers and Lifestyle Study who underwent clinical reclassification (blinded to biomarker findings) at 54-month follow-up. The individuals were split into estimated high and low NAB groups based on a cutoff of 1.5 standardized uptake value ratio. We assessed the predictive accuracy of the high and low NAB groupings based on progression to mild cognitive impairment or AD according to clinical reclassification at 54-month follow-up. Results: Twelve percent of HCs with estimated high NAB progressed in comparison to 5% of HCs with estimated low NAB (odds ratio 2.4). Forty percent of the participants with MCI who had estimated high NAB progressed in comparison to 5% of the participants with MCI who had estimated low NAB (odds ratio 12.3). These ratios are in line with those reported for Pittsburgh compound B-PET results. Individuals with estimated high NAB had faster rates of memory decline than those with estimated low NAB. Conclusion: These findings suggest that a simple blood-based signature not only provides estimates of NAB but also predicts cognitive decline and disease progression, identifying individuals at risk of progressing toward AD at the prodromal and preclinical stages.
DOI
10.1212/WNL.0000000000003094
Access Rights
subscription content
Comments
Burnham, S. C., Rowe, C. C., Baker, D., Bush, A. I., Doecke, J. D., Faux, N. G., . . . Villmagne, V. L. (2016). Predicting Alzheimer disease from a blood-based biomarker profile. Neurology, 87(11), 1093-1101. Available here.